TENAX THERAPEUTICS, INC. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Tenax's Phase 3 LEVEL trial of TNX-103 (oral levosimendan) for pulmonary hypertension with heart failure enrolled 241 patients (120 TNX-103, 121 placebo) and failed the primary endpoint of 6-minute walk distance improvement (3.5m difference, p=0.63). However, in prespecified subgroup analyses, patients with baseline walk distance <333m showed +26.3m improvement vs placebo (p=0.0112), and NT-proBNP fell 49% vs placebo across the overall population (p=0.0001). Company plans to request FDA Type C meeting to discuss enriched Phase 3 trial targeting sicker patients.
Why this rating
Primary endpoint failure is materially adverse for a $23.8M-market-cap biotech; salvageable subgroup data and biomarker signals offer narrow path forward, but regulatory approval probability has declined significantly. Major de-risking event with binary clinical outcome.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.